ArchiveSee matrix →ES
Supplement

DMAE

A compound (dimethylaminoethanol) promoted for cognition and, in cosmetics, for skin firmness.
Category
Scientific evidence
Low-moderate
Number of findings
2
Sources
Our own summaries · Cited studies
Recommended dose and how to use
Oral or in creams, depending on the product.

How to take it

Oral or in creams, depending on the product.

Safety

Avoid in pregnancy (preclinical data on malformations). Orally, cognitive evidence is poor.

Interactions

Caution with cholinergic drugs; avoid in pregnancy.

Effect by goal · level of evidence

Skin firmness (topical)

improves (modest) Low-moderate RCT (AA)
Small effect

Small tightening effect in a facial gel.

View the study (RCT) →

Cognition

no clear effect Low small trials (A)
No clear effect

Weak evidence in humans.

In depth

⏱ 3 min read

DMAE, or dimethylaminoethanol, is a choline analog found naturally in small amounts in oily fish (anchovies, sardines, salmon), where it is synthesized endogenously as a metabolic precursor of acetylcholine; marketed since the 1970s as a nootropic supplement (precursor of acetylcholine, a neurotransmitter for memory and attention) and, more recently, as a topical cosmetic ingredient for improving skin tone and the apparent reduction of wrinkles, DMAE has an interesting clinical profile with heterogeneous data and with safety questions that deserve careful attention, particularly for the oral formulation in prolonged use.

The proposed mechanism of action for cognitive indications is to serve as a precursor in the brain synthesis of acetylcholine, theoretically increasing the availability of this neurotransmitter involved in memory, attention, and learning; for skin indications, the mechanism is attributed to effects on dermal microcirculation and modulation of the localized inflammatory response, together with a possible firming effect on the subcutaneous facial muscle tone.

Cognitive function and attention disorders

In past decades, DMAE was used for attention-deficit and hyperactivity disorders in children (previously marketed as Deanol in some European countries), with data from older trials suggesting modest benefits on behavior and attention in children; more recent data are less optimistic and current pharmacological options (methylphenidate, atomoxetine) are clearly superior, which has relegated DMAE to anecdotal use for this indication.

In adults without cognitive deficit and as a nootropic, clinical data are limited and inconsistent; commercial claims of significant improvements in memory, attention, or mood are not supported by rigorous modern trials, and DMAE is positioned as one of the nootropics with a reasonable mechanistic basis but with modest clinical data.

Topical cosmetic application

In dermatological cosmetics, DMAE 3 percent gel applied topically to the face and neck has shown modest improvements in skin tone and perceived firmness in some small studies, an indication with limited clinical support and with very modest effect sizes compared with pharmacological or procedural cosmetic treatments (topical retinol, glycolic acid, botulinum toxin for dynamic wrinkles).

How to take it and precautions

The oral doses historically used range from 100 to 500 milligrams per day, divided into one or two doses with or without food; typical commercial products contain 100-300 mg per capsule; for cosmetic use, 3 percent gels applied once a day to specific facial areas according to the product's instructions.

The safety considerations are particularly important with oral DMAE and deserve specific mention: animal studies have documented embryonic developmental abnormalities with DMAE during gestation, which has led to its classification as a probable teratogen and to its absolute contraindication in pregnancy; the adverse effects described in chronic oral use include headache, insomnia, irritability, muscle tension, and occasionally confusion or paradoxical depression (especially in older adults); people with epilepsy or unstabilized psychiatric disorders should be cautious; those taking anticholinergics (some antidepressants, antihistamines, drugs for incontinence) may have a pharmacodynamic interaction; prolonged use of oral DMAE is not considered prudent without medical supervision because of the suboptimal safety profile; topical cosmetic use has a more favorable safety profile and the adverse effects described are mild (erythema, local skin dryness); in pregnancy and breastfeeding, both formulations (oral and topical) should be avoided as a precaution because of the animal teratogenicity data; cosmetic products with DMAE can produce transient visible effects but long-term skin safety data are limited; the reasonable position is to consider oral DMAE a supplement with an unfavorable risk/benefit profile for prolonged use in people without a specific clinical indication supported by their treating physician.

References

  1. Knobel, M.; Wolman, M.B.; Mason, E. (1956). Deanol in the treatment of hyperkinetic children. Psychopharmacology 1. PMID 13391870
  2. Dimpfel, W.; Wedekind, W.; Keplinger, I. (2003). Efficacy of dimethylaminoethanol (DMAE) containing vitamin-mineral drug combination on EEG patterns in the presence of different emotional states. Eur J Med Res 8, 5. PMID 12805222
  3. Uhoda, I. et al. (2002). Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel. Skin Res Technol 8, 3. doi:10.1034/j.1600-0846.2002.10342.x
  4. Re, O. (1974). 2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Ther Res Clin Exp 16, 11. PMID 4279052
  5. Fisman, M. et al. (1981). Dimethylaminoethanol in Alzheimer's disease. Am J Psychiatry 138, 7. doi:10.1176/ajp.138.7.970

Information, not medical advice. Scientific evidence reflects the quality of the studies.

Loading assistant…